Results 51 to 60 of about 22,921 (208)
Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity
Advanced Science, EarlyView.Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu +8 more
wiley +1 more source
Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine.
PLoS ONE, 2020 Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome in patients treated with a ten ...
Pierre Bories +15 more
doaj +2 more sources
Myelodysplasia in a psoriasis patient receiving etanercept : Cause or coincidence? [PDF]
, 2018 Peer reviewedFinal Accepted ...
Ayoub, Othman Hadi +3 more
core +3 more sources
Advanced Science, EarlyView.This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
Azacitidine-induced bullous pemphigoid-like localized toxic reaction [PDF]
Einstein (São Paulo)Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation ...
Rodrigo Brêtas Emerich Nogueira +7 more
doaj +1 more source
The Iraqi Journal of Veterinary Medicine, 2023 Aplastic anemia, marked by deficiencies in hematopoietic stem cells, leads to peripheral blood pancytopenia and hypocellular bone marrow. This study aimed to evaluate the therapeutic efficacy of cyclosporine and azacitidine, administered either ...
ghanem taher, Huda F Hasn
doaj +1 more source
Fatal Bone marrow necrosis following azacitidine and granulocyte colony-stimulating factor administration in a patient with high-risk myelodysplastic syndrome [PDF]
, 2015 Azacitidine, which has the capacity to induce DNA hypomethylation in vitro, is currently available for treatment of myelodysplastic syndrome (MDS). As a result of some trials, azacitidine has been recently recommended as a frontline therapy for elderly ...
加藤 丈夫 +4 more
core +1 more source
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer [PDF]
, 2017 Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor ...
Attwood, Kristopher +16 more
core +3 more sources
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Noonan syndrome (NS) is a genetically heterogeneous disorder characterized by a broad spectrum of clinical features resulting from dysregulation of the RAS/MAPK pathway. Although complex genotypes are increasingly recognized in NS, cases harboring two distinct pathogenic variants in different NS genes remain extremely rare.
Francesco Prevedello +10 more
wiley +1 more source
Experimental Hematology & Oncology, 2020 Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carried out to compare the two agents.
Bingbing Wen +3 more
doaj +1 more source